MedPath

Tumor Exosome Liquid Biopsy Strategy to Diagnose Pancreatic Cancer

Conditions
Pancreatic
Registration Number
NCT06108531
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Brief Summary

This is an observational study of patients diagnosed with pancreatic cancer by pathology, with a control group of patients with pathology suggestive of benign pancreatic lesions and normal subjects, and the diagnostic ability of exosomes to identify patients with pancreatic cancer was assessed through the detection of exosomes in the peripheral blood.

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
400
Inclusion Criteria

Diagnosis of pancreatic cancer confirmed by imaging (case) Diagnosis of chronic pancreatitis confirmed by imaging (hospital control)

Exclusion Criteria

The pathology diagnosis and imaging does not matched Patients with other malignant tumors Patients with other severe systemic diseases

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Characterization of proteins in tumor exosomes from patients with pancreatic cancerUp to 2 years from start of study

We will select specific protein A from circulating exosomes of pancreatic cancer patients for further analysis.

The expression of protein A in the circulating exosomes from patientsUp to 2 years from start of study

By detecting the expression of protein A in circulating exosomes of patients. the ROC curve of A+ circulating exosomes will be compared to clinical standard tumor biomarkers (e.g., CA199) in pancreatic cancer patients.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Xinhua Hospital, Affiliated to Shanghai Jiao Tong University, School of Medicine

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath